Why the study?
Do calcium antagonists retard the progression of chronic renal disease?
Do calcium antagonists retard the progression of chronic renal disease?
Calcium antagonists may offer renal protective effects independent of blood pressure reduction, similar to the benefits seen with ACE inhibitors.
Answers are grounded in this paper and cite their sources.
May support calcium antagonists for renal protection beyond BP reduction; leaves open whether they slow chronic kidney disease progression.
End-stage renal disease, which signifies irreversible renal failure, constitutes a major and growing public health problem worldwide. The striking increase in end-stage renal disease has catalyzed clinical and investigative focus on pharmacologic interventions to retard progression to this condition. Increasing evidence indicates that some classes of antihypertensive medications may confer a greater effect than others in slowing progression of renal disease despite similar levels of blood pressure reduction. Substantive data indicate that angiotensin converting enzyme inhibition preferentially retards the progression of renal disease, primarily by protecting the injured kidney from hemodynamically mediated glomerular damage. Newer studies suggest that calcium antagonists also have diverse properties, which are independent of their renal microcirculatory effects that might afford renal protection.
No takes yet. Share an insight, caveat, or question.
Murray Epstein (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: